Fig. 3.
RAS-targeting peptide-PROTACs. Anti-RAS biologics are genetically fused to an E3 ubiquitin ligase resulting in recruitment of the complex to RAS, polyubiquitination and subsequent proteasomal degradation. The peptide-PROTAC, however, can be recycled to initiate multiple rounds of RAS degradation.